李波, 何欣, 罗宏涛, 杨荣. 探讨CK7 CK20和TTF-1在判断转移性腺癌原发病灶中的应用价值[J]. 中国肿瘤临床, 2012, 39(10): 683-686. DOI: 10.3969/j.issn.1000-8179.2012.10.015
引用本文: 李波, 何欣, 罗宏涛, 杨荣. 探讨CK7 CK20和TTF-1在判断转移性腺癌原发病灶中的应用价值[J]. 中国肿瘤临床, 2012, 39(10): 683-686. DOI: 10.3969/j.issn.1000-8179.2012.10.015
shu
Bo LI, Xin HE, Hong-tao LUO, Rong YANG. Value of Combined Detection of CK7, CK20, and TTF-1 Expression in Evaluating the Origin of Metastatic Carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(10): 683-686. DOI: 10.3969/j.issn.1000-8179.2012.10.015
Citation: Bo LI, Xin HE, Hong-tao LUO, Rong YANG. Value of Combined Detection of CK7, CK20, and TTF-1 Expression in Evaluating the Origin of Metastatic Carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(10): 683-686. DOI: 10.3969/j.issn.1000-8179.2012.10.015
shu

探讨CK7 CK20和TTF-1在判断转移性腺癌原发病灶中的应用价值

Value of Combined Detection of CK7, CK20, and TTF-1 Expression in Evaluating the Origin of Metastatic Carcinoma

    摘要
  • 摘要:
      目的  了解CK7、CK20及TTF-1在腺癌中的表达情况, 探讨联合应用这3种标志物对判断转移性腺癌原发部位的价值。
      方法  采用组织芯片和免疫组织化学的
      方法  , 检测CK7、CK20与TTF-1在229例腺癌及10例食管鳞癌组织中的表达。
      结果  3种抗体在不同组织来源肿瘤中的表达可以组合成8种模式: CK7+/CK20-/TTF-1+: 甲状腺乳头状癌阳性率较高(50%); CK7+/CK20-/TTF-1-: 涎腺腺癌(94.44%)、乳腺小叶癌(85.71%)、卵巢浆液性癌(71.43%)、胆囊腺癌(63.64%)、宫颈腺癌(61.54%), 阳性率较高; CK7+/CK20+/TTF-1+: 阳性率均不高; CK7+/CK20+/TTF-1-: 阳性率均不高; CK7-/CK20-/TTF-1+: 阳性率均不高; CK7-/CK20-/TTF-1-: 前列腺癌(100%)、食管鳞癌(100%)、肾透明细胞癌(90.90%), 阳性率较高; CK7-/CK20+/TTF-1+: 阳性率均不高; (CK7-/CK20+/TTF-1-: 肠腺癌(66.67%)阳性率较高;
      结论  联合检测(CK7、CK20及TTF-1抗体有助于判断部分转移性腺癌的器官来源, 缩小原发肿瘤的搜寻范围。

     

    Abstract:
      Objectives  To investigate the expression of CK7, CK20.and TTF-1 in adenocarcinoma, and summarize a valuable regular pattern to determine their organic source.
      Methods  A total of 229 cases of adenocarcinoma tumor tissues and 10 cases of esophageal squamous cell carcinoma were studied by the tissue array technology and immunohistochemistry for CK7, CK20, and TTF-1.
      Results  Eight types of combined patterns of CK7, CK20, and TTF-1 in different cancers were observed: CK7+/ CK20- / TTF-1+: papillary thyroid carcinoma(50%); CK7+ / CK20- / TTF-1-: salivary gland adenocarcinoma(94.44%), lobular carcinoma(85.71%). ovarian serous carcinoma(71.43%), gallbladder adenocarcinoma(63.64%), and cervical adenocarcinoma(61.54%), high positive rates; CK7+ / CK20+ / TTF-1+: none had a high positive rate: CK7+ / CK20+ / TTF-1-: none had a high positive rate: CK7- / CK20-/ TTF-1+: none had a positive rate; CK7- / CK20- / TTF-1-: prostate cancer(100%).esophageal squamous cell carcinoma(100%). and renal cell carcinoma(90.90%), high positive rates; CK7+ / CK20+ / TTF-1 +: none had a positive rate; and CK7-/ CK20+ / TTF-1-: intestinal adenocarcinoma(66.67%), high positive rate.
      Conclusion  The combined detection of CK7.CK20, and TTF-1 expression helps determine the origins of some metastatic adenocarcinomas, minimize the range of such origins, and establish the groundwork for the origin evaluation of adenocarcinomas.

     

    • HTML全文
    • 参考文献(13)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回